Aptevo Therapeutics Revises Term Loan Agreement With MidCap Financial; Reduces Cash Requirements by $18 Million
Defers Principal Repayments to February 2020 and Reduces Restricted Cash Covenant
Aptevo to Announce Second Quarter 2018 Financial Results on August 9, 2018
SEATTLE, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that it has executed a new agreement amending the terms of its original $20 million term loan agreement with MidCap Financial Trust.
Under the new agreement, the timeline for Aptevo to begin making principal repayments has been extended from August 1, 2018 to February 1, 2020, with an opportunity for further deferral through August 1, 2020. In addition, the amount of restricted cash that Aptevo is required to maintain on its balance sheet has been reduced from $10 million to $5 million.
“We are extremely pleased to execute a new agreement with MidCap,” commented Jeff Lamothe, Chief Financial Officer for Aptevo. “The revised terms of the new agreement will increase our available cash by approximately $18 million over the next 18 months, extending our cash runway and providing increased flexibility with regard to Aptevo’s future capital requirements. We are pleased to continue to work with the team at MidCap and look forward to our continued collaboration.”
“Aptevo is a much stronger organization today than we were two years ago,” continued Mr. Lamothe. “Our portfolio includes a leading bispecific antibody therapeutic platform, ADAPTIR™, which includes 2 clinical-stage programs and multiple next-generation immunotherapeutic candidates with best-in-class potential advancing, as well as a marketed product, IXINITY®, demonstrating solid growth. I am very excited about our future and the opportunities ahead for Aptevo – for good reason, as we continue to execute on our business plan and build value for our stockholders.”
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer or autoimmune diseases. Aptevo has two ADAPTIR antibody candidates currently in clinical development and a broad pipeline of novel investigational-stage bispecific antibody candidates focused in immuno-oncology and autoimmune disease and inflammation. For more information, please visit www.aptevotherapeutics.com
About MidCap Financial
MidCap Financial is a middle market-focused, specialty finance firm that provides senior debt solutions to businesses across all industries. The firm’s years of experience, strong balance sheet, and flexibility make it a lender of choice for companies across all stages of growth and complexity. MidCap Financial’s debt solutions focus in five areas: (i) General and Healthcare Asset-Based working capital loans collateralized by third-party accounts receivable and other assets, (ii) Leveraged loans to companies backed by private equity sponsors, (iii) Life Sciences loans to VC-backed and public pharmaceutical, biotech, and medical device companies, (iv) Real Estate loans on all types of commercial properties, medical office buildings, various types of senior housing and skilled nursing properties, and (v) Lender Finance term loans or revolvers provided across the consumer and commercial finance sectors. Additional information about MidCap Financial can be found at www.midcapfinancial.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo’s outlook, financial performance or financial condition, Aptevo’s technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, milestones, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevo’s actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo’s business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 13, 2018 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo’s expectations in any forward-looking statement.
Source: Aptevo Therapeutics Stacey JurchisonSenior Director, Investor Relations and Corporate Communications206-859-6628 JurchisonS@apvo.com